NeoGenomics(FRA) NG9

Market Cap€2.02B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€15.48

-1.59%

-0.25Today

NeoGenomics Financials at a Glance

Market Cap

€2.02B

Revenue (TTM)

€657.08

Net Income (TTM)

-€44.40

EPS (TTM)

-€0.35

P/E Ratio

-45.55

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€15.48

Volume

Open

€15.48

Price

€15.48

Volume

Open

€15.48

Previous Close

€15.48

Daily Range

€15.48 - €15.48

52-Week Range

€6.20 - €15.83

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€15.48

Volume

Open

€15.48

Previous Close

€15.48

Daily Range

€15.48 - €15.48

52-Week Range

€6.20 - €15.83

Estimated Earnings Date

N/A

NG9 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

2,500

CEO

Anthony P. Zook

Website

www.neogenomics.com

NG9 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-6.28%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-2.20%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€2.02B

Shares Outstanding

128.47M

Volume

Avg. Volume

7.47

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

NeoGenomics Performance Analysis

NeoGenomics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 485,005,192	18.4%
2023	2023-12-31	EUR 547,252,300	12.8%
2024	2024-12-31	EUR 610,679,158	11.6%
2025	2025-12-31	EUR 644,467,668	5.5%

NeoGenomics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -1.10	1775.9%
2023	2023-12-31	EUR -0.65	-41.3%
2024	2024-12-31	EUR -0.57	-11.4%
2025	2025-12-31	EUR -0.75	30.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€173.44

+1.1%

Gross Profit

€76.42

+1.2%

Gross Margin

44.06%

+1.1%

Market Cap

€2.02B

N/A

Market Cap/Employee

€0.64

N/A

Employees

2,500

N/A

Net Income

€1.92

-0.0%

EBITDA

€5.10

-2.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€519.47

+7.6%

Total Debt

€392.17

+1.1%

Accounts Receivable

€153.57

+1.2%

Inventory

€23.74

+0.8%

Long Term Debt

€387.42

+1.1%

Short Term Debt

€4.75

+1.4%

Return on Assets

-3.75%

+0.5%

Return on Invested Capital

-6.05%

+1.5%

Free Cash Flow

€10.03

+0.7%

Operating Cash Flow

€17.12

+0.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About NG9

What is the current price of NeoGenomics?

NeoGenomics is trading at €15.48 per share.

What is the 52-week range for NeoGenomics?

Over the past 52 weeks, NeoGenomics has traded between €6.20 and €15.83.

How much debt does NeoGenomics have?

As of the most recent reporting period, NeoGenomics reported total debt of €392.17M.

How much cash does NeoGenomics have on hand?

NeoGenomics reported €127.30M in cash and cash equivalents in its most recent financial results.

What is NeoGenomics’s dividend yield?

NeoGenomics does not currently have a dividend yield.

NeoGenomics(FRA) NG9

NeoGenomics Financials at a Glance

NG9 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NeoGenomics

NG9 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NeoGenomics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NG9

What is the current price of NeoGenomics?

What is the 52-week range for NeoGenomics?

How much debt does NeoGenomics have?

How much cash does NeoGenomics have on hand?

What is NeoGenomics’s dividend yield?

Premium Investing Services